Literature DB >> 33981003

Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer.

Francesco Davide Naso1, Dalila Boi2, Camilla Ascanelli3, Georgiana Pamfil1, Catherine Lindon4, Alessandro Paiardini5, Giulia Guarguaglini6.   

Abstract

The Aurora-A kinase regulates cell division, by controlling centrosome biology and spindle assembly. Cancer cells often display elevated levels of the kinase, due to amplification of the gene locus, increased transcription or post-translational modifications. Several inhibitors of Aurora-A activity have been developed as anti-cancer agents and are under evaluation in clinical trials. Although the well-known mitotic roles of Aurora-A point at chromosomal instability, a hallmark of cancer, as a major link between Aurora-A overexpression and disease, recent evidence highlights the existence of non-mitotic functions of potential relevance. Here we focus on a nuclear-localised fraction of Aurora-A with oncogenic roles. Interestingly, this pool would identify not only non-mitotic, but also kinase-independent functions of the kinase. We review existing data in the literature and databases, examining potential links between Aurora-A stabilisation and localisation, and discuss them in the perspective of a more effective targeting of Aurora-A in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33981003      PMCID: PMC8195736          DOI: 10.1038/s41388-021-01766-w

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

1.  The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.

Authors:  Y Takahashi; P Sheridan; A Niida; G Sawada; R Uchi; H Mizuno; J Kurashige; K Sugimachi; S Sasaki; Y Shimada; K Hase; M Kusunoki; S Kudo; M Watanabe; K Yamada; K Sugihara; H Yamamoto; A Suzuki; Y Doki; S Miyano; M Mori; K Mimori
Journal:  Ann Oncol       Date:  2015-01-28       Impact factor: 32.976

Review 2.  Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.

Authors:  Giulia Bertolin; Marc Tramier
Journal:  Cell Mol Life Sci       Date:  2019-09-27       Impact factor: 9.261

3.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines.

Authors:  S Sen; H Zhou; R A White
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

Review 4.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

5.  The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

Authors:  A B D'Assoro; T Liu; C Quatraro; A Amato; M Opyrchal; A Leontovich; Y Ikeda; S Ohmine; W Lingle; V Suman; J Ecsedy; I Iankov; A Di Leonardo; J Ayers-Inglers; A Degnim; D Billadeau; J McCubrey; J Ingle; J L Salisbury; E Galanis
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

6.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Authors:  Shubha Anand; Sue Penrhyn-Lowe; Ashok R Venkitaraman
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

7.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.

Authors:  H Zhou; J Kuang; L Zhong; W L Kuo; J W Gray; A Sahin; B R Brinkley; S Sen
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

Review 8.  Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.

Authors:  Min Yan; Chunli Wang; Bin He; Mengying Yang; Mengying Tong; Zijie Long; Bing Liu; Fei Peng; Lingzhi Xu; Yan Zhang; Dapeng Liang; Haixin Lei; Sen Subrata; Keith W Kelley; Eric W-F Lam; Bilian Jin; Quentin Liu
Journal:  Med Res Rev       Date:  2016-07-13       Impact factor: 12.944

9.  Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.

Authors:  Margret Aradottir; Sigridur T Reynisdottir; Olafur A Stefansson; Jon G Jonasson; Asgerdur Sverrisdottir; Laufey Tryggvadottir; Jorunn E Eyfjord; Sigridur K Bodvarsdottir
Journal:  J Pathol Clin Res       Date:  2014-11-07

10.  AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.

Authors:  Xi Liu; Zhaoxia Li; Yue Song; Rui Wang; Lei Han; Qixue Wang; Kui Jiang; Chunsheng Kang; Qingyu Zhang
Journal:  Oncotarget       Date:  2016-05-31
View more
  4 in total

1.  News from around the RNA world: new avenues in RNA biology, biotechnology and therapeutics from the 2022 SIBBM meeting.

Authors:  Virginia Brancato; Ilaria Brentari; Lucia Coscujuela Tarrero; Mattia Furlan; Francesco Nicassio; Michela A Denti
Journal:  Biol Open       Date:  2022-10-14       Impact factor: 2.643

2.  EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures.

Authors:  Matthias Peindl; Claudia Göttlich; Samantha Crouch; Niklas Hoff; Tamara Lüttgens; Franziska Schmitt; Jesús Guillermo Nieves Pereira; Celina May; Anna Schliermann; Corinna Kronenthaler; Danjouma Cheufou; Simone Reu-Hofer; Andreas Rosenwald; Elena Weigl; Thorsten Walles; Julia Schüler; Thomas Dandekar; Sarah Nietzer; Gudrun Dandekar
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

3.  The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.

Authors:  Chiara Naro; Monica De Musso; Francesca Delle Monache; Valentina Panzeri; Pierre de la Grange; Claudio Sette
Journal:  J Exp Clin Cancer Res       Date:  2021-12-20

Review 4.  Regulating the regulator: a survey of mechanisms from transcription to translation controlling expression of mammalian cell cycle kinase Aurora A.

Authors:  Roberta Cacioppo; Catherine Lindon
Journal:  Open Biol       Date:  2022-09-07       Impact factor: 7.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.